Mesoblast Limited Sustainability Profile
Mesoblast Limited, an innovative leader in regenerative medicine, is headquartered in Australia and operates extensively across North America, Europe, and Asia. Founded in 2004, the company has made significant strides in developing advanced cell-based therapies, particularly in the fields of orthopaedics, cardiovascular diseases, and inflammatory conditions. Mesoblast's core products, including its proprietary allogeneic cell therapy platforms, are designed to address unmet medical needs with unique mechanisms of action that promote healing and tissue regeneration. The company has achieved notable milestones, including successful clinical trials and partnerships that enhance its market position in the biotechnology sector. With a commitment to transforming patient care, Mesoblast continues to be at the forefront of innovation in regenerative medicine.
DitchCarbon Score
How does Mesoblast Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mesoblast Limited's score of 16 is lower than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mesoblast Limited's reported carbon emissions
Mesoblast Limited, headquartered in Australia, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges from the company. This lack of data suggests that Mesoblast may not have established formal commitments to reduce its carbon footprint or may not publicly disclose such information. In the context of the biotechnology industry, many companies are increasingly adopting science-based targets and sustainability initiatives to address climate change. However, without specific emissions data or commitments from Mesoblast, it is challenging to assess their environmental impact or climate strategy. As the industry evolves, it is anticipated that Mesoblast may consider implementing climate commitments in line with global sustainability trends.
How Carbon Intensive is Mesoblast Limited's Industry?
How Carbon Intensive is Mesoblast Limited's Location?
Mesoblast Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mesoblast Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
